Find Clinical Trial

Efficacy and safety of 3 doses of S 47445 versus placebo in patients with Alzheimer’s disease at mild to moderate stages with depressive symptoms. A 24-week international, multi-centre, randomized, double-blind, placebo-controlled phase II study in monotherapy followed by an optional 28-week extension period in co-administration with donepezil.


← Back
Study Phase

Phase 2

Therapeutic Area

Neuropsychiatric Diseases

IndicationAlzheimer's disease
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

S047445

Active Substance CodeS047445
Protocol CodeCL2-47445-011
EudraCT Code2014-001519-38
NCT CodeNCT02626572


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility